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Abstract. 
 
Protein kinase C 
 
b
 
II
 
 (PKC 
 
b
 
II
 
) has been im-
plicated in proliferation of the intestinal epithelium. To 
investigate PKC 
 
b
 
II
 
 function in vivo, we generated 
transgenic mice that overexpress PKC 
 
b
 
II
 
 in the intesti-
nal epithelium. Transgenic PKC 
 
b
 
II
 
 mice exhibit hyper-
proliferation of the colonic epithelium and an increased 
susceptibility to azoxymethane-induced aberrant crypt 
foci, preneoplastic lesions in the colon. Furthermore, 
transgenic PKC 
 
b
 
II
 
 mice exhibit elevated colonic
 
b
 
-catenin levels and decreased glycogen synthase ki-
nase 3
 
b
 
 activity, indicating that PKC 
 
b
 
II
 
 stimulates the 
Wnt/adenomatous polyposis coli (APC)/
 
b
 
-catenin pro-
liferative signaling pathway in vivo. These data demon-
strate a direct role for PKC 
 
b
 
II
 
 in colonic epithelial cell 
 
proliferation and colon carcinogenesis, possibly through 
 
activation of the APC/
 
b
 
-catenin signaling pathway.
Key words: protein kinase C • colon carcinogenesis • 
signal transduction • proliferation • transgenic mice
C
 
OLON
 
 carcinogenesis is a complex multistep process
involving progressive disruption of homeostatic
mechanisms controlling intestinal epithelial cell
proliferation, differentiation, and programmed cell death.
This disruption appears to be mediated by dietary and en-
vironmental factors that modulate intestinal epithelial cell
signaling pathways, as well as genetic mutation of trans-
forming oncogenes and deletion or mutation of DNA re-
pair enzymes and tumor suppressor genes (Bertagnolli et
 
al., 1997). Recent studies have demonstrated the primary
 
importance of the Wnt/APC/
 
b
 
-catenin signaling pathway in
colon carcinogenesis (Pennisi, 1998). Mutations in either
 
APC or 
 
b
 
-catenin that lead to activation of this pathway
are present in the vast majority of colon cancers and co-
lonic carcinoma cell lines (Pennisi, 1998).
Accumulating evidence implicates protein kinase C
 
(PKC)
 
1
 
 in intestinal epithelial cell proliferation and colon
carcinogenesis both in rodents and humans (Weinstein,
1990; Chapkin et al., 1993). PKC activity is higher in ac-
 
tively proliferating colonic epithelial cells than in their
quiescent counterparts (Craven and DeRubertis, 1987),
suggesting a role for PKC activation in epithelial cell pro-
liferation. A link between PKC and colon carcinogenesis
comes from the observation that components of cancer-
promoting high fat diets lead to an increase in both colonic
epithelial cell PKC activity and cellular proliferation (Cra-
ven and DeRubertis, 1988; Reddy et al., 1996). High fat
diet-induced hyperproliferation is thought to predispose
the colonic epithelium to further genetic and biochemical
changes associated with progression along the carcino-
genic pathway. PKC has also been shown to play a requi-
site role in the Wnt/APC/
 
b
 
-catenin proliferative signaling
pathway, suggesting a plausible molecular mechanism by
which PKC could stimulate colonic epithelial cell prolifer-
ation and colon carcinogenesis (Cook et al., 1996).
Several lines of evidence indicate that the PKC 
 
b
 
II
 
isozyme (PKC 
 
b
 
II
 
) is selectively involved in colonic epithe-
lial cell proliferation and colon carcinogenesis. First, PKC
 
b
 
II
 
 is the most responsive of the PKC isozymes expressed
in the colonic epithelium to activation by secondary bile
acids (Pongracz et al., 1995). Secondary bile acid levels are
elevated in rodents fed a cancer-promotive high fat diet
and this increase has been implicated in early carcinogenic
events (for review see Reddy, 1975). Second, expression of
most colonic PKC isozymes (e.g., PKC 
 
a
 
, 
 
d
 
, and 
 
z
 
) is re-
duced in the presence of chronically elevated diacylglyc-
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1. 
 
Abbreviations used in this paper:
 
 ACF, aberrant crypt foci; AOM,
azoxymethane; APC, adenomatous polyposis coli; DAG, diacylglycerol;
DBA, dolichos biflorus agglutinin; FABP, fatty acid binding protein;
 
GSK-3
 
b
 
, glycogen synthase kinase 3
 
b
 
; PAS, periodic acid Schiff; PKC,
 
protein kinase C; PKC 
 
b
 
II
 
, protein kinase C 
 
b
 
II 
 
isozyme; PNA, peanut ag-
glutinin; RT-PCR, reverse transcriptase PCR; TUNEL, TdT-mediated
dUTP-biotin nick end labeling; UEAI, Ulex europaeus-I.
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erol (DAG), such as is present in preneoplastic colonic ep-
ithelial cells (Wali et al., 1991; Jiang et al., 1996; Chapkin
et al., 1997; Jiang et al., 1997). However, intestinal PKC
 
b
 
II
 
 is largely resistant to such activator-mediated down-
regulation (Saxon et al., 1994, Sauma et al., 1996). Third,
the levels of PKC 
 
b
 
II
 
 are dramatically elevated both during
the initial stages of tumorigenesis and in colonic carcino-
mas when compared with normal colonic tissue (Craven
and DeRubertis, 1992; Davidson et al., 1994, 1998). Fi-
nally, PKC 
 
b
 
II
 
 is directly involved in colon carcinoma cell
proliferation in vitro (Lee et al., 1993; Sauma et al., 1996).
These studies provide compelling but indirect evidence
that PKC 
 
b
 
II
 
 plays an important role in intestinal epithelial
cell proliferation and colon carcinogenesis, and are con-
sistent with our studies demonstrating that PKC 
 
b
 
II
 
 is
required for leukemia cell proliferation (Murray et al.,
1993). Therefore, we hypothesized that PKC 
 
b
 
II
 
 is directly
involved in intestinal epithelial cell proliferation in vivo
and that elevated colonic PKC 
 
b
 
II
 
 expression and activity
would enhance colon carcinogenesis. To directly test this
hypothesis, we generated transgenic mice that express ele-
vated levels of PKC 
 
b
 
II
 
 in the intestinal epithelium. These
animals exhibit both hyperproliferation of the colonic epi-
thelium and an increased susceptibility to colon carcino-
genesis. Furthermore, our data indicate that the 
 
b
 
-catenin/
APC proliferative signaling pathway is stimulated by PKC
 
b
 
II
 
 in these animals.
 
Materials and Methods
 
Production and Maintenance of Transgenic Mice
 
A transgene construct consisting of the rat liver fatty acid binding protein
(FABP) promoter (
 
2
 
596 to 
 
1
 
21; kindly provided by Dr. Jeffrey Gordon,
Washington University, St. Louis, MO), the full-length human PKC 
 
b
 
II
 
cDNA, and the SV40 large T antigen polyadenylation signal sequence was
produced by conventional cloning methods. The resulting PKC 
 
b
 
II
 
 trans-
gene construct was confirmed by direct microsequencing before microin-
jection. The pFABP/PKC 
 
b
 
II
 
 transgene construct was propagated in the
mammalian expression vector pREP4 and the transgene insert was ex-
cised using NheI (5
 
9
 
) and XbaI (3
 
9
 
), purified, and microinjected into
C57BL/6J 
 
3
 
 C3H/HeJ F
 
2
 
 mouse oocytes as previously described (Hogan
et al., 1994). The microinjections and generation of transgenic founder
mice were conducted at the University of Texas Medical Branch Trans-
genic Mouse Facility. Transgenic founder mice were identified by South-
ern blot analysis. In brief, genomic tail DNA (5 
 
m
 
g) was digested to com-
pletion with Taq I (Roche), resolved by agarose gel electrophoresis,
transferred to nylon membrane (Amersham), and transgenic DNA de-
tected with a radiolabeled probe corresponding to the SV40 polyadenyla-
tion sequence. Three transgenic founder animals were identified from a
screen of 120 live births. Transgene copy number was determined for each
transgenic line by quantitative Southern blot analysis as previously de-
scribed (Hogan et al., 1994). Genotype was confirmed by slot blot analysis
using a radiolabeled probe corresponding to the polyadenylation se-
quences within the transgene (Sambrook et al., 1989).
Founder mice were mated with C57BL/6J mice (The Jackson Labora-
tory) to establish the transgene on a stable genetic background. Trans-
genic PKC 
 
b
 
II
 
 mice and progeny were bred and housed in microisolator
cages maintained at constant temperature and humidity on a 12-h on/12-h
off light cycle in a pathogen-free barrier facility. Mice were provided a
standard autoclavable chow (Purina 7012, 5% fat) and autoclaved water
ad libitum.
 
Detection of Transgenic PKC 
 
b
 
II
 
 RNA
 
Total RNA was extracted from tissue samples using a Totally RNA kit
(Ambion). Reverse transcription was carried out using 6 
 
m
 
g RNA, 1 
 
m
 
g
oligo(dT) primer, 10 mM dithiothreitol, 0.5 mM dNTPs, and 200 U Super-
Script II reverse transcriptase (GIBCO BRL). Amplification of the trans-
 
genic RNA was carried out using 20 ng of the following primers, which
amplify human PKC 
 
b
 
II
 
 but not endogenous mouse PKC 
 
b
 
II
 
: forward, 5
 
9
 
CGTCCTCATTGTCCTC 3
 
9
 
; reverse 5
 
9
 
 GACCTTGGTTCCCTGACTG
3
 
9
 
. An optimized amplification program of denaturation (94
 
8
 
C, 15 s), an-
nealing (56
 
8
 
C, 15 s), and extension (74
 
8
 
C, 45 s) for 40 cycles using PCR Su-
permix (GIBCO BRL) was used. Human brain RNA was used as a posi-
tive control; mouse brain RNA and samples incubated without reverse
transcriptase served as negative controls.
 
PKC Immunoblot and Immunohistochemical Analysis
 
Immunoblot analysis for PKC 
 
b
 
II
 
 expression in mouse colonic epithelium
was performed essentially as previously described (Davidson et al., 1994).
In brief, mice were killed by CO
 
2
 
 asphyxiation, the colons were isolated
and slit open longitudinally and rinsed well with PBS, and the colonic epi-
thelium was scraped using a plastic coverslip. Total cell extracts were pre-
pared in RIPA buffer [50 mM Tris, pH 7.2, 150 mM NaCl, 2 mM EDTA,
0.4 mM EGTA, 20 
 
m
 
M NaF, 0.5% deoxycholate, 1% NP-40, 0.1% SDS,
0.1 mM Na
 
3
 
VO
 
4
 
, 25 
 
m
 
g/ml aprotinin, 25 
 
m
 
g/ml leupeptin, 25 
 
m
 
g/ml pepsta-
tin, 1 
 
m
 
g/ml soybean trypsin inhibitor, and 34.5 
 
m
 
g/ml 4-(2-aminoethyl)
benzene sulfonyl fluoride]. Equal amounts (30 
 
m
 
g) of protein were sub-
jected to immunoblot analysis using an isotype-specific antibody for PKC
 
b
 
II
 
 (Santa Cruz Biotechnology).
Immunohistochemistry was performed using an enhanced biotinyl tyra-
mide system (New England Nuclear) on sections from the proximal and
distal colon fixed in ethanol, embedded in paraffin, and sectioned (5 
 
m
 
m)
as previously described (Jiang et al., 1995), with the following modifica-
tions. After deparaffinization and rehydration of tissues, sections were
treated with 3% hydrogen peroxide in methanol to inhibit endogenous
peroxidase, blocked with TNB reagent (Dupont New England Nuclear),
and incubated with polyclonal antibody to PKC 
 
b
 
II
 
 (Hocevar and Fields,
1991). Specificity was confirmed using antibody preincubated with excess
antigen peptide as previously described (Jiang et al., 1995). Sections were
incubated with biotinylated secondary antibody followed by addition of
streptavidin-conjugated peroxidase. Biotinyl tyramide amplification re-
agent was then added followed by a second streptavidin-peroxidase incu-
bation. Visualization was with DAB chromagen.
 
Measurement of Colonic Epithelial Cell Cytokinetics
 
12-wk-old mice were killed and their colons were dissected and measured
for overall length. The distal colon (1 cm from rectal end) was fixed in 4%
paraformaldehyde and processed for histology as described previously
(Jiang et al., 1995). Tissues were embedded in paraffin, sectioned (5-
 
m
 
m
thickness) and stained with hematoxylin and eosin. 25 full-length, longitu-
dinally cut crypts from each animal were analyzed for crypt height (mi-
crometer) and number of cells per crypt height. 25 crypts cut on the cross-
section at random height were counted to determine the average crypt
circumference (in number of cells). These data were used to calculate cell
size (crypt height in micrometer/crypt height in cell number) and estimate
the total cells per crypt (mean cells per crypt column 
 
3 
 
mean crypt cir-
cumference).
 
Proliferation. 
 
Cell proliferation was determined by immunohistochemi-
cal detection for proliferating cell nuclear antigen (PCNA) in distal colon
sections. Primary antibody against PCNA (PC10 clone; DAKO) was di-
luted 1:50 in PBS and preincubated with 1:200 biotinylated anti–mouse
IgG (Santa Cruz Biotechnology) overnight at 4
 
8
 
C. After deparaffiniza-
tion, sections were processed for antigen retrieval as described by the
manufacturer (DAKO), treated with 1% hydrogen peroxide for 10 min to
inactivate endogenous peroxidases, and blocked with normal goat serum.
The slides were then incubated with the PCNA/anti–mouse IgG antibody
conjugate for 60 min at room temperature. Antigen–antibody complexes
were detected with avidin and peroxidase–labeled biotin (ABC staining
system; Santa Cruz Biotechnology) and visualized with DAB. Slides were
counterstained with hematoxylin to provide contrast. 20 full-length, longi-
tudinally cut crypts were divided into thirds and scored visually for cells
staining darkly for PCNA (Lin et al., 1996). The labeling index (percent of
labeled cells) and proliferative zone (highest cell from the bottom of the
crypt staining for PCNA divided by the total cells per crypt height) were
calculated for each set of animals.
 
Differentiation. 
 
The differentiation status of colonic epithelial cells was
measured by detection of the specific binding of three different lectins.
After deparaffinization, sections were incubated for 60 min at room tem-
perature in normal goat serum. Three different biotinylated lectins (doli-
chos biflorus agglutinin [DBA], peanut agglutinin [PNA], and Ulex euro-
paeus-I [UEAI]; Vector Labs.) were diluted to 10 
 
m
 
g/ml in PBS. Sections
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were incubated with one of the three lectin solutions for 60 min at room
temperature. Sections were then washed in three changes of PBS and in-
cubated with 5 
 
m
 
g/ml of rhodamine red-X–conjugated Streptavidin (Jack-
son Immunoresearch Labs.) in PBS for 30 min at room temperature. After
three 5-min washes in PBS, sections were mounted in aqueous media con-
taining 95% glycerol in PBS and analyzed by fluorescence microscopy.
Sections were also analyzed histologically by Alcian blue/periodic acid
Schiff (PAS) staining for detection of mature, mucin-producing goblet cells.
 
Apoptosis. 
 
The percentage of cells undergoing apoptosis (apoptotic in-
dex) was determined in paraformaldehyde-fixed distal colon tissue by the
TdT-mediated dUTP-biotin nick end labeling of fragmented DNA
(TUNEL) assay (Gavrieli et al., 1992) using the apoTACS kit from Trevi-
gen. The tissue sections were counterstained with methyl green. 100 longi-
tudinally cut, full-length crypts were scored for apoptotic cells based on a
combination of positive staining and morphological criteria as previously
described (Kerr et al., 1995).
 
Carcinogen Treatment and Aberrant Crypt
Foci Analysis
 
40 (20 transgenic PKC 
 
b
 
II
 
 mice, 20 nontransgenic littermates) 6–7-wk-old
female mice were injected intraperitoneally with azoxymethane (10 mg/kg
body wt) or saline weekly for 2 wk as previously described (Chang et al.,
1997). At 5 and 20 wk after the second injection, five animals per group
were killed by CO
 
2
 
 asphyxiation and the colons were removed. The colons
were flushed with PBS to remove fecal pellets, slit open longitudinally,
and fixed flat between two pieces of filter paper under a glass plate in 70%
ethanol for 24 h. Fixed colons were stained with 0.2% methylene blue in
PBS for 5 min before being mounted on a glass slide for observation at
low magnification (
 
3
 
40) on a light microscope. Aberrant crypt foci (ACF)
were scored blindly by a single observer (A.P. Fields) for total number
and multiplicity (number of crypts/focus) using previously defined criteria
(McLellan et al., 1991).
 
b
 
-Catenin Immunoblot Analysis and Glycogen Synthase 
Kinase 3
 
b
 
 Kinase Assay
 
Colonic epithelia from transgenic and nontransgenic mice were scraped
and equal amounts of protein from total tissue lysates were subjected to
immunoblot analysis using a specific 
 
b
 
-catenin polyclonal antibody (Santa
 
Cruz Biotechnology Inc.) or a specific GSK-3
 
b
 
 monoclonal antibody
(Transduction Laboratories). For glycogen synthase kinase (GSK)-3
 
b
 
 ki-
nase assay, colonic epithelium scrapings were solubilized in lysis buffer [10
mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 1% Tri-
ton X-100, 150 mM NaCl, 25 
 
m
 
g/ml aprotinin, 25 
 
m
 
g/ml leupeptin, 25 
 
m
 
g/
ml pepstatin, 1 
 
m
 
g/ml soybean trypsin inhibitor, 34.5 
 
mg/ml 4-(2-amino-
ethyl) benzene sulfonyl fluoride, 20 mM NaF, and 0.1 mM Na3VO4]. Ly-
sates containing 300 mg of protein were precleared with 75 ml of protein A
agarose and then added to 75 ml of protein A agarose beads that had been
preincubated with 5 mg of anti–GSK-3b monoclonal antibody (Transduc-
tion Labs.). Samples were incubated for 1 h at 48C, and beads were pel-
leted and washed once with lysis buffer and once with kinase assay buffer
(8 mM MOPS, pH 7.4, 0.2 mM EDTA, 10 mM Mg acetate, and 0.1 mM
ATP). The washed and pelleted beads were then resuspended in 40 ml of
kinase assay buffer containing 10 mCi [g32P]ATP and 250 mmol of GSK-
3b–specific substrate peptide (Upstate Biotechnology, Inc.). Reactions
were incubated for 20 min at 258C and stopped by pelleting the beads and
adding the supernatant to 20 ml of 40% trichloroacetic acid. Reactions
were spotted on P-81 filters and washed three times in 0.75% phosphoric
acid and once with acetone. Incorporated radioactive phosphate was
quantitated by Cerenkov counting. Nonspecific and background counts
were calculated by performing parallel assays with a nonphosphorylatable
GSK-3b substrate peptide.
Results
Generation and Identification of PKC bII
Transgenic Mice
To investigate the role of PKC bII in colonic epithelial cell
biology, we generated transgenic mice overexpressing
PKC bII in the intestinal epithelium. For this purpose, we
used the rat liver FABP promoter, which has been well
characterized to target transgene expression to the intesti-
nal epithelium (Cohn et al., 1991; Simon et al., 1993). A
schematic diagram of the transgene construct is presented
in Fig. 1 A. The FABP promoter (2596 to 121) was fused
Figure 1. (A) Generation and characterization of
transgenic PKC bII mice. Schematic diagram of the
PKC bII transgene construct. A transgene construct
consisting of the rat liver FABP promoter (2596 to
121), full-length human PKC bII cDNA, and the
SV40 large T antigen polyadenylation signal se-
quence was generated. Restriction sites for excision
of the construct from the cloning vector (NheI/
XbaI), for generation of radiolabeled probe
(BamHI/XbaI), and for digestion of genomic DNA
for Southern blot analysis (Taq I) are indicated with
arrows. (B) Southern blot analysis to identify
founder transgenic mice. Tail DNA was digested
with Taq I to generate a 453-bp fragment containing
the SV40 polyadenylation sequence from the trans-
gene (see A). 5 mg of digested genomic DNA was
resolved by gel electrophoresis and transferred to
nitrocellulose, and the membrane was incubated
with 32P-labeled probe to the SV40 polyadenylation
sequence. M, radiolabeled DNA mol wt markers;
54, 61, 78, and 92 indicate genomic DNA from four
founder animals carrying the transgene construct;
wt, genomic DNA from a nontransgenic mouse; *
indicates an anomalous size band reacting with the
transgene probe. (C) Transgenic PKC bII RNA is
expressed in the colon of transgenic mice. Total RNA was isolated from scraped colonic epithelium from a litter of mice in the 54 trans-
genic line. Reverse transcription and amplification was carried out using primers specific to regions of sequence divergence between hu-
man and mouse PKC bII. Amplification products were separated on agarose gels and the product was visualized by ethidium bromide
staining. Human brain RNA was used as a positive control (1 control); tg, RNA from transgenic animals; wt, RNA from nontransgenic
animals. Genotype was confirmed by slot blot analysis.
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to the cDNA for human PKC bII and the SV40 poly A sig-
nal sequence by conventional cloning. Southern blot anal-
ysis of tail DNA identified four potential transgenic
founders (designated Nos. 54, 61, 78, and 92) from 120 live
births (Fig. 1 B). Animal 92 gave a reactive band of higher
mol wt than the expected 453 bp Taq 1 fragment gener-
ated from the intact transgene (Fig. 1, asterisk). Further
analysis using overlapping PCR primer sets demonstrated
that this animal contained a truncated transgene, whereas an-
imals 54, 61, and 78 contained multiple copies of the intact
transgene construct. All three of the founder animals were
fertile and subsequent analysis of progeny by quantitative
Southern blot analysis demonstrated that they carried 6, 15,
and 31 copies of the transgene, respectively. Furthermore, all
three transgenic lines exhibit germline transmission of the
transgene to subsequent progeny (data not shown).
Characterization of PKC bII Transgene Expression
PKC bII transgenic RNA expression was detected by re-
verse transcriptase (RT)-PCR using primers specific for
the human PKC bII transgene. A representative RT-PCR
analysis of a litter of mice from the 54 transgenic line is
shown in Fig. 1 C. As can be seen, transgenic PKC bII
mRNA is detected in the colonic epithelium of all three
transgenic mice, but not in nontransgenic littermates. Fur-
ther analysis demonstrated that PKC bII transgene expres-
sion is fully penetrant, being detected in the colonic epi-
thelium of all transgenic mice tested. Furthermore, no
false positive RT-PCR products have been detected in
nontransgenic animals, demonstrating the specificity of
the RT-PCR primers for the human PKC bII transgene
construct. Similar results were obtained in the 61 and 78
transgenic lines (data not shown).
We next determined the level of PKC bII protein expres-
sion in the colonic epithelium of transgenic mice. Colonic
epithelial cell lysates from transgenic and nontransgenic
animals from the 54 transgenic line were prepared and
subjected to immunoblot analysis using a PKC bII iso-
zyme-specific antibody (Hocevar and Fields, 1991). Con-
Figure 2. PKC bII protein is overex-
pressed in the colons of transgenic
mice. (A) Immunoblot analysis for
PKC bII. A litter of mice from the 54
transgenic line was killed, the colons
were isolated and scraped, and total
cell lysates (30 mg) were subjected to
immunoblot analysis using a PKC
bII–specific antibody as previously
described (Murray et al., 1993). Den-
sitometric analysis indicates that
transgenic animals express an aver-
age of fivefold higher level of PKC
bII than do nontransgenic litter-
mates. tg, lysates from transgenic an-
imals; wt, lysates from nontransgenic
animals; 1, rat brain extract used as
positive control. (B and C) Immuno-
histochemical localization of PKC bII
in proximal colon of transgenic mice.
Proximal colon from transgenic mice
and nontransgenic littermates in the
54 transgenic line were fixed in 70% ethanol, embedded in paraffin, sectioned, and immunostained for PKC bII as described in Materi-
als and Methods. In nontransgenic colon (B), endogenous PKC bII localizes to the mid-crypt areas and to the luminal surface of the
crypts. In transgenic colon (C), PKC bII staining is greater than in the nontransgenic animal and is observed along the entire crypt axis.
Original magnification: 3400. Bars, 10 mm.
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sistent with the presence of transgenic PKC bII mRNA,
PKC bII protein levels in the colonic epithelium of trans-
genic mice are elevated relative to their nontransgenic lit-
termates (Fig. 2 A). Transgenic PKC bII exhibits a relative
molecular mass of z85 kD, comigrating with mouse brain
PKC bII used as a positive control. Similar results were ob-
tained in the small intestine of these animals and from ani-
mals in the 61 and 78 transgenic lines (data not shown).
Quantitation of PKC bII expression by densitometric anal-
ysis of the immunoblots indicated that 54 line transgenic
mice express an average of fivefold more PKC bII protein
than do nontransgenic littermates. Immunoprecipitation
kinase assays showed an approximately fivefold increase
in calcium- and phospholipid-dependent PKC bII activity
in the colonic epithelium of transgenic mice, demonstrat-
ing that transgenic PKC bII is catalytically active and ex-
hibits the same cofactor dependence of endogenous PKC/
bII (data not shown). Animals in the 54 transgenic line
gave a consistently high level of transgene expression and
therefore this line was selected for further analysis.
We next assessed the pattern of transgenic PKC bII pro-
tein expression within the colonic epithelium by immuno-
histochemistry (Fig. 2, B and C). For this purpose, tissue
from the proximal colon of transgenic and nontransgenic
mice was immunostained for PKC bII. Consistent with our
RT-PCR and immunoblot results, the colonic epithelium
from transgenic animals (Fig. 2 C) exhibits increased im-
munostaining for PKC bII when compared with nontrans-
genic littermates (Fig. 2 B). In nontransgenic mice, PKC
bII staining is observed in the mid-crypt regions and on the
luminal surface of the epithelium. In transgenic animals,
PKC bII staining is greatest in the mid-crypt region but is
detectable throughout the entire crypt axis. Previous char-
acterization of the transgene promoter demonstrated that
the rat liver FABP promoter is active in both proliferating
and postmitotic cells in the colonic epithelium of trans-
genic mice (Hansbrough et al., 1991). The distribution of
endogenous PKC bII overlaps that of the stem cell popula-
tion, which is located in the mid-crypt region in the proxi-
mal colon (Sato and Ahnen, 1992). In the proximal colon,
maturing colonic epithelial cells migrate from the prolifer-
ative mid-crypt region toward the base and the luminal
surface of the crypt (Sato and Ahnen, 1992). The fact that
endogenous PKC bII expression colocalizes with the stem
cell population is consistent with the hypothesis that PKC
bII plays a functional role in colonic epithelial cell prolifer-
ation. Transgenic PKC bII expression was detected in both
the proximal and distal colon, indicating transgene expres-
sion throughout the colonic epithelium.
Effect of Transgene Expression on Colonic
Crypt Morphometry
To investigate the biological effects of overexpression of
PKC bII in the colonic epithelium, we analyzed the follow-
ing colonic morphometric parameters: colon length, co-
lonic crypt height (in micrometer and cell number), crypt
circumference (in cell number), and cell size (crypt height
in micrometer/crypt height in cell number) (Table I). This
analysis revealed no statistical difference in the length of
the colon, cell size, crypt height in micrometers, or crypt
circumference between transgenic and nontransgenic lit-
termates. However, colonic crypts from transgenic mice
tended to be longer and have a larger circumference than
those from nontransgenic mice. In addition, a highly sig-
nificant increase in the number of cells per crypt height,
and in the total number of cells per crypt, was observed in
transgenic mice (Table I). Similar results were obtained in
a second transgenic mouse line (line 78; 22.2 cells per crypt
height in transgenic versus 20.7 in nontransgenic mice, P 5
0.009; and 356.4 total cells per crypt in transgenic versus
321.1 in nontransgenic mice, P 5 0.007), indicating that
this effect is due to the presence of the PKC bII transgene
rather than an insertional mutagenic event. Both of these
cytokinetic parameters are highly regulated and are deter-
mined by the balance among cell proliferation, differentia-
tion, and apoptosis. These results demonstrate that in-
creased expression of PKC bII disrupts one or more of the
homeostatic mechanisms regulating cell number in the co-
lonic epithelium.
Increased PKC bII Expression Induces 
Hyperproliferation of the Colonic Epithelium
Elevated PKC bII could increase the number of colonic ep-
ithelial cells by increasing the level of proliferation, or by
decreasing differentiation and/or apoptosis, in the colonic
crypt. To distinguish between these possibilities, each of
these cytokinetic parameters was measured. Immunohis-
tochemical staining for PCNA revealed that the colonic
epithelium from transgenic mice contain significantly
more PCNA-positive cells than those from nontransgenic
mice (Fig. 3). Quantitation of PCNA-positive nuclear
staining (indicative of cells in S-phase; Lin et al., 1996;
Shpitz et al., 1997) gave a labeling index of 28.3 6 0.2% for
transgenic mice compared with 21.4 6 0.9% for nontrans-
genic mice (Table II). This difference is highly significant
(P 5 0.0001) and clearly contributes to the increase in
crypt cell number observed in transgenic mice. The differ-
ence in labeling index was most pronounced in the bottom
third of the crypts, the region containing the stem cell pop-
ulation in the distal colon. The size of the proliferative
zone (calculated as the highest labeled cell in the crypt
column) was also larger in transgenic colons; however,
this difference was not statistically significant (Table II).
Taken together, these data demonstrate that elevated
PKC bII expression stimulates hyperproliferation of the
stem cell population residing within the base of the crypt,
rather than stimulating postmitotic cells higher in the crypt
to reenter the cell cycle.
The differentiation state of the colonic epithelium was
Table I. Effect of PKC bII Transgene Expression on 
Morphometric Parameters in the Colon
Control Transgenic P value
Colon length (cm) 8.5 6 0.2 8.6 6 0.1 NS
Crypt height (mm) 102.6 6 3.9 108.3 6 2.3 NS
Crypt height (No. cells) 20.1 6 0.4 22.3 6 0.2 0.0002
Cell size (crypt height [mm]/ 5.1 6 0.1 4.9 6 0.1 NS
crypt height [No. cells])
Crypt circumference (No. cells) 16.3 6 0.3 16.8 6 0.2 NS
Total No. cells per crypt 327.7 6 7.2 372.8 6 2.5 0.0002
Results are shown as means 6 SEM on a sample size of 10 mice/group. NS, not sig-
nificantly different.
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examined by staining with a panel of lectins and his-
tochemical markers to identify the major differentiated
colonic epithelial cell lineages. Fig. 4, A and B, shows dis-
tal colonic epithelium from transgenic and nontransgenic
mice stained with the two histochemical stains, Alcian blue
and PAS, that detect goblet cells. The staining pattern
seen in transgenic and nontransgenic animals is indistin-
guishable. Mucin production was detected by staining with
several fluorescently labeled lectins (Fig. 4, C–H). DBA
binds fairly uniformly to mucin-producing cells in normal
distal colonic epithelium (Fig. 4, C and D; Campo et al.,
1988; Caldero et al., 1989; Chang et al., 1997; Hong et al.,
1997). PNA gives a golgi (supranuclear) staining pattern
on a subset of mucin-producing enterocytes (Fig. 4, E and
F; Freeman, 1983; Campo et al., 1988; Caldero et al., 1989;
Boland and Ahnen, 1995) and UEAI gives low level stain-
ing in normal mucosa of the distal colon (Fig. 4, G and H;
Caldero et al., 1989). Analysis of the number and location
of cells staining with the various lectins revealed no signifi-
cant changes in the number of goblet cells or in the inten-
sity or pattern of lectin labeling in transgenic PKC bII ver-
sus nontransgenic mice. These data indicate that increased
expression of PKC bII has no demonstrable effect on the
differentiation status of the major colonic enterocytic cell
lineages.
The level of apoptosis in the colonic epithelium was
measured using an in situ TUNEL assay (Fig. 5, A and B).
An example of TUNEL staining of an apoptotic cell,
which typically occurs near the top of the crypt, is shown in
Fig. 5 A. As expected, we detected a very low level of apop-
tosis in the colon of transgenic PKC bII and nontransgenic
mice. The apoptotic index in the distal colon of nontrans-
genic mice was not significantly different from that in
transgenic PKC bII mice (Fig. 5 B). Apoptosis is thought to
contribute to the loss of cells required to maintain a bal-
ance with cell proliferation within the colonic epithelium
(Chang et al., 1997; Potten et al., 1997). However, apop-
totic cells are quickly eliminated in the colonic crypt, so
that apoptosis is detected at a very low level (Hall et al.,
1994; Merritt et al., 1994; Risio et al., 1996). Our results are
similar to the level of apoptosis in mouse colon reported
by others (Merritt et al., 1994; Risio et al., 1996), and dem-
onstrate that increased expression of PKC bII has no sig-
nificant effect on the level of apoptosis in the colonic epi-
thelium.
Transgenic PKC bII Mice Are More Susceptible to 
Formation of Carcinogen-induced Aberrant Crypt Foci
Increased cellular proliferation is a significant risk factor
for development of colon cancer (Chang et al., 1997; Ein-
spahr et al., 1997). Therefore, we assessed whether trans-
genic PKC bII mice exhibit an increased susceptibility to
colon carcinogenesis. 1,2-dimethylhydrazine and its me-
tabolite, azoxymethane (AOM), are organ-specific carcin-
ogens that have been extensively characterized for their
ability to induce colon cancer in rodents (Deschner and
Long, 1977; Deschner et al., 1979). AOM reproducibly in-
duces colon tumors that exhibit many of the same genetic
and signal transduction defects identified in human colon
carcinomas (Deschner et al., 1977; Deschner et al., 1979;
Figure 3. Transgenic PKC bII
mice exhibit increased prolif-
eration of the colonic epithe-
lium. 12-wk-old transgenic
and nontransgenic mice were
killed and their colons were
isolated and fixed in para-
formaldehyde as previously
described (Chang et al.,
1997). Sections were stained
for PCNA with DAB
(brown) using the ABC stain-
ing system (Santa Cruz Bio-
technology). Sections were
counterstained with hematox-
ylin (blue). A shows the non-
transgenic mouse colon, and
B shows the transgenic mouse
colon. Original magnification:
3400. Bars, 10 mm.
Table II. Effect of PKC bII Transgene Expression on 
Proliferative Parameters in the Colon
Control Transgenic P value
Labeling index
Entire crypt 21.4 6 0.9 28.3 6 0.2 0.0001
Top 1/3 crypt 0.2 6 0.2 0 6 0 NS
Middle 1/3 crypt 13.8 6 2.5 17.8 6 1.0 NS
Bottom 1/3 crypt 50.0 6 2.7 67.5 6 1.4 0.0005
Proliferative zone
Entire crypt column 37.1 6 2.5 41.4 6 1.1 NS
Results are shown as means 6 SEM on a sample size of four to five mice/group. NS, 
not significantly different, (P . 0.05).
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Erdman et al., 1997; Maltzman et al., 1997; DeFilippo et
al., 1998; Sheng et al., 1998). AOM also induces ACF,
which represent well-established preneoplastic colonic le-
sions in both rodents and humans (McLellan and Bird,
1988; McLellan et al., 1991; Takayama et al., 1998). Both
the number and multiplicity (i.e., number of crypts per fo-
cus) of ACF are highly predictive of subsequent tumor de-
velopment (Magnuson et al., 1993; Bird, 1995; Shivapurkar
Figure 4. Transgenic PKC bII mice show no
change in colonic epithelial cell differentiation.
(A and B) Alcian blue/PAS staining. Mucin-con-
taining goblet cells in colonic epithelium of non-
transgenic (A) and transgenic PKC bII (B) mice
were stained with Alcian blue/PAS. (C–H) Lec-
tin staining. Sections from nontransgenic (C, E,
and G) and transgenic (D, F, and H) mouse co-
lonic epithelium were incubated with three dif-
ferent biotinylated lectins and detected with avi-
din-conjugated rhodamine red-X. C and D,
DBA; E and F, PNA; G and H, UEAI. Arrow-
heads indicate Golgi staining in PNA-stained
sections. Bars, 10 mm.
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et al., 1997). Therefore, AOM-induced colon carcinogene-
sis is a highly relevant model for human colon cancer.
To determine whether transgenic PKC bII mice differ
from nontransgenic mice in their sensitivity to AOM-
induced colon carcinogenesis, 6–7-wk-old transgenic PKC
bII mice and nontransgenic littermates (five mice/group)
received either AOM (10 mg/kg body wt) or saline by in-
traperitoneal injection once a week for 2 wk. At 5 and 20
wk after the second AOM injection, mice were killed and
their colons were analyzed for the presence of ACF. In
agreement with the literature (Bird, 1987; McLellan and
Bird, 1988; McLellan et al., 1991), we observed no ACF in
saline-injected animals, confirming that ACF arise as a re-
sult of AOM exposure. Colons from both transgenic and
nontransgenic animals treated with AOM contained ACF
exhibiting the distinguishing characteristics described by
Bird and colleagues (Bird, 1987; McLellan and Bird, 1988;
McLellan et al., 1991). Specifically, ACF appeared as en-
larged crypts, often three or four times the size of adjacent
crypts, that were raised above the surface of the surround-
ing mucosa. ACF characteristically stained darker than
surrounding crypts, had thicker than normal intercryptal
spaces, and exhibited thickening of the crypt wall, sugges-
tive of epithelial stratification. The crypt lumens in ACF
were elongated and often serrated, in contrast to the
round, smooth lumens of normal crypts. ACF contained
either a single aberrant crypt or involved two or more ad-
jacent crypts. Fig. 6 A shows the morphology of a typical
ACF consisting of three crypts from an AOM-treated ani-
mal. The total number of ACF/colon and the multiplicity
of ACF was determined at 5 and 20 wk after the last AOM
injection (Fig. 6, B–D). AOM-treated transgenic mice had
a statistically significant increase in the total number of
ACF/colon and in the number of ACF of higher multiplic-
ity at both 5 and 20 wk (Fig. 6, B and C). At 20 wk, the to-
tal number of ACF did not increase significantly from that
measured at 5 wk; however, the number of ACF of higher
multiplicity did increase in transgenic PKC bII mice (Fig. 6
D). Interestingly, at 5 wk, although the total number of
ACF and the number of ACF of higher multiplicity were
greater in transgenic mice, the average multiplicity of ACF
in these two groups did not differ (Fig. 6 D). However, by
20 wk, transgenic mice exhibited an increase not only in
the number of ACF but also in the average crypt multiplic-
ity (Fig. 6 D). Since the number of ACF, particularly those
of higher multiplicity, are highly predictive of subsequent
colon tumor incidence, these data demonstrate that trans-
genic PKC bII mice are more susceptible to AOM-induced
colon carcinogenesis than nontransgenic littermates. Fur-
thermore, these data suggest that elevated PKC bII is in-
volved not only in the early promotive phase of ACF de-
velopment but also in their progression to lesions of higher
multiplicity and malignant potential.
The APC/b-Catenin Signaling Pathway Is Activated in 
the Colonic Epithelium of Transgenic PKC bII Mice
Colonic epithelial cell proliferation is under the control of
the Wnt/APC/b-catenin proliferative signaling pathway
(Pennisi, 1998). PKC has recently been demonstrated to
play a key role in Wnt/wingless signaling in tissue culture
cells (Cook et al., 1996). Selective PKC inhibitors can
block Wnt-mediated inhibition of GSK-3b activity, whereas
activation of PKC with PMA leads to inactivation of
GSK-3b kinase activity in the absence of Wnt (Cook et al.,
1996). GSK-3b is a constitutively active serine/threonine
kinase that is a critical downstream target in the Wnt sig-
naling pathway. GSK-3b–mediated phosphorylation of
APC facilitates binding of b-catenin to APC, which targets
b-catenin for degradation. The ability of PKC to inhibit
GSK-3b activity is probably due to its direct phosphoryla-
tion of GSK-3b, since PKC has been shown to directly
phosphorylate GSK-3b and inhibit its activity in vitro
(Goode et al., 1992). To determine whether PKC bII acti-
vates the Wnt/APC/b-catenin pathway in vivo, we as-
sessed GSK-3b levels and activity in the colonic epithe-
lium of transgenic PKC bII mice (Fig. 7, A and B).
Immunoblot analysis reveals that GSK-3b protein levels
Figure 5. Transgenic PKC
bII mice exhibit no change in
apoptosis. (A) Detection of
apoptosis in the colonic epi-
thelium by in situ TUNEL.
Distal colonic epithelium
was isolated and fixed in
paraformaldehyde as previ-
ously described (Chang et al.,
1997) and cells undergoing
apoptosis were detected by
an in situ TUNEL method. A
representative apoptotic cell is indicated by the arrow. (B) Quan-
titative analysis of in situ TUNEL staining. 100 crypts from trans-
genic and nontransgenic mice were scored for apoptotic cells and
the apoptotic index was calculated (percentage of apoptotic
cells). Results are expressed as the mean 6 SEM. Bar, 10 mm.
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are similar in transgenic and nontransgenic mice (Fig. 7
A). However, immunoprecipitation kinase assays demon-
strate that GSK-3b activity in transgenic mice is 50% of
that observed in nontransgenic littermates (Fig. 7 B). The
observed decrease in GSK-3b activity is due to a decrease
in the specific kinase activity of the enzyme since GSK-3b
expression was unchanged in transgenic PKC bII mice
(Fig. 7 A). The extent of GSK-3b inhibition is similar to
that observed in response to optimal concentrations of ei-
ther soluble Wnt or PMA in fibroblasts in vitro (Cook et
al., 1996). As another measure of Wnt pathway activation,
b-catenin protein levels were assessed by immunoblot
analysis (Fig. 7, C and D). b-catenin levels are elevated in
transgenic PKC bII mice when compared with nontrans-
genic littermates (Fig. 7 C). Densitometric analysis of the
immunoblot data indicate that on average b-catenin levels
are z40% higher in transgenic PKC bII mice. These data
indicate that the Wnt/APC/b-catenin signaling pathway
can be stimulated by bII and provide a plausible molecular
mechanism by which PKC bII causes hyperproliferation
and increased susceptibility to colon carcinogenesis in
these animals.
Discussion
Colonic Crypt Homeostasis/Role of 
(Hyper)proliferation in Susceptibility to
Colon Carcinogenesis
Colon carcinogenesis is a multistep process involving the
progressive loss of growth control mechanisms and accu-
mulation of genetic mutations that result in an increasing
level of neoplasia (Bertagnolli et al., 1997). The process
of multistage carcinogenesis has been described as “a
progressive disorder in signal transduction” (Weinstein,
1990). According to this model, nongenetic changes in
normal signal transduction pathways which increase the
susceptibility to further genetic “hits” and therefore play a
critical role in the pathogenesis of colon cancer occur early
in the carcinogenic process. However, the nature of these
early cancer-promotive changes is not well understood.
Members of the PKC family of enzymes have been impli-
cated in the regulation of colonic cell proliferation, differ-
entiation, and apoptosis. PKC bII plays a direct role in cel-
lular proliferation in both human leukemia cells and colon
cancer cell lines (Murray et al., 1993; Sauma et al., 1996),
and increases in PKC bII expression are early events in co-
lon carcinogenesis in vivo (Davidson et al., 1998). Our
present data demonstrate that this increase in PKC bII ex-
pression plays a promotive role in colon carcinogenesis.
To directly assess the role of PKC bII in colonic epithe-
lial cell proliferation and colon carcinogenesis, we devel-
oped a transgenic mouse model in which PKC bII is over-
expressed in the intestinal epithelium. Transgenic PKC bII
mice exhibit hyperproliferation of the colonic epithelium
characterized by an increase in the labeling index and an
increase in the number of cells per colonic crypt. Interest-
ingly, no significant changes were observed in colonocyte
differentiation status or apoptotic index, indicating a selec-
tive effect of PKC bII on the proliferative program of the
colonic epithelium. Although we cannot eliminate the pos-
sibility that subtle changes have occurred in the regulation
of differentiation or susceptibility to apoptosis, our data
clearly demonstrate that the change in proliferation is a
major contributing factor to the increased colonic crypt
cell number observed in transgenic PKC bII mice.
Figure 6. Transgenic PKC bII
mice are more susceptible to
AOM-induced ACF forma-
tion. (A) An ACF from an
AOM-treated mouse. Colons
from AOM-treated mice were
cut longitudinally from cecum
to anus, fixed flat in 70% etha-
nol, and stained with 0.2% me-
thylene blue for 5 min. Colons
were scored for ACF under
low magnification (340) using previously defined criteria for
ACF (Bird, 1987; McLellan and Bird, 1988). A representative
ACF from an AOM-treated animal is shown. This ACF involves
three adjacent crypts. Bar, 100 mm. (B–D) Transgenic PKC bII
mice have increased levels of AOM-induced ACF. 6-wk-old fe-
male mice from the 54 line (transgenic and nontransgenic litter-
mates) were injected with AOM (10 mg/kg body wt) weekly for
2 wk. At 5 and 20 wk after the second injection the mice were
killed and the colons were analyzed for the presence of ACF as
described in panel A. wt, nontransgenic; tg, transgenic. (B) ACF
analysis at 5 wk after treatment. Total ACF per animal and ACF
involving .1 crypt were plotted for both transgenic and non-
transgenic animals. For each group of animals, n 5 5. (C) ACF
analysis at 20 wk after treatment. Total ACF per animal and ACF
involving .2 crypt were plotted for both transgenic and non-
transgenic animals. For each group of animals, n 5 5. (D) Crypt
multiplicity of ACF at 5 and 20 wk. The average crypt multiplic-
ity for ACF in nontransgenic and transgenic mice was calculated
at 5 and 20 wk. For each group of animals, n 5 5. Error bars rep-
resent the SEM.
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Increased proliferation is an important risk factor for in-
duction of colon cancer and is a key biomarker of preneo-
plastic events (Chang et al., 1997; Einspahr et al., 1997).
Our data indicate that PKC bII acts early in the carcino-
genic pathway to increase the proliferation of the colonic
epithelium, perhaps making it more susceptible to further
genetic mutations and formation of preneoplastic lesions,
including ACF. The effect of increased PKC bII expression
on the susceptibility to induction of colon cancer was
tested using a well-characterized rodent carcinogenesis
model (Deschner and Long, 1977; Deschner et al., 1979).
AOM-induced colon tumors are a good model for spo-
radic human colon cancer because they exhibit many of
the same properties as human colon tumors, including in-
creased proliferation, development of tumors predomi-
nantly in the distal colon, and the presence of many of the
same genetic mutations found in human tumors. In addi-
tion, ACF, the earliest preneoplastic lesions observed in
this model, are also thought to be preneoplastic lesions in
humans (Pretlow et al., 1992; Takayama et al., 1998). ACF
exhibit many of the early phenotypic markers of colon
cancer including increased proliferation and frequent mu-
tations in the APC and ras genes (Pretlow et al., 1993;
Smith et al., 1994; Shivapurkar et al., 1997). We demon-
strate that increased PKC bII expression makes transgenic
mice more susceptible to AOM-induced colon carcinogen-
esis as measured by an increase in the total number of
ACF and in the number of ACF of higher multiplicity than
nontransgenic mice. ACF are highly predictive of subse-
quent tumor formation and multiplicity in the rodent car-
cinogenesis model and of adenoma formation and colon
cancer risk in humans (Magnuson et al., 1993; Bird, 1995;
Roncucci et al., 1991). Our data indicate that elevated
PKC bII expression not only promotes ACF formation,
but also stimulates progression of these lesions. These re-
sults suggest that PKC bII plays a critical role at multiple
stages in the colon carcinogenic pathway.
A Model for the Role of PKC bII in Sporadic
Colon Cancer
Accumulating evidence suggests that PKC bII plays a di-
rect role in intestinal epithelial cell proliferation and colon
carcinogenesis in both rodents and humans. PKC bII levels
and activity are elevated in preneoplastic and neoplastic
colons, demonstrating that these changes precede colon
carcinoma development (Craven and DeRubertis, 1992;
Wali et al., 1995; Davidson et al., 1998). Here, we demon-
strate that overexpression of PKC bII in the colonic epithe-
lium leads to hyperproliferation and increased susceptibil-
ity to colon carcinogenesis. Furthermore, we demonstrate
that elevated PKC bII leads to inhibition of GSK-3b activ-
ity and an increase in b-catenin levels. These observations
are consistent with in vitro data demonstrating a requisite
role for PKC in the Wnt proliferative signaling pathway
(Cook et al., 1995), and suggest that PKC bII may play
such a role in vivo. Further studies will be required to de-
termine whether PKC bII–mediated activation of this
pathway is required for its ability to stimulate proliferation
and cancer susceptibility in the transgenic mouse setting.
Taken together, the data lead us to propose a molecular
mechanism by which PKC bII stimulates colonic epithelial
cell hyperproliferation and increased colon carcinogenesis
in transgenic mice (Fig. 8). In this model, PKC bII either
directly or indirectly leads to GSK-3b inactivation. PKC
has been shown to phosphorylate GSK-3b and inactivate
the enzyme in vitro (Goode et al., 1992), suggesting that
PKC bII can inhibit GSK-3b by direct phosphorylation and
inactivation. Inhibition of GSK-3b leads to an accumula-
tion of b-catenin by decreasing the interaction of b-cate-
nin with APC, which targets b-catenin for degradation.
Accumulation of b-catenin causes Tcf-dependent tran-
scriptional activation of growth-related genes to stimulate
colonocyte proliferation (Pennisi, 1998). The APC/b-cate-
nin pathway is a major site for mutation during colon car-
Figure 7. Transgenic PKC bII mice exhibit de-
creased GSK-3b activity and increased b-catenin
levels. (A) Immunoblot analysis for GSK-3b in
the colonic epithelium of transgenic (tg) and non-
transgenic (wt) mice. (B) Immunoprecipitation
kinase assays for GSK-3b were performed on
scraped colon extracts from transgenic and non-
transgenic mice. Results were normalized to
GSK-3b activity in nontransgenic animals. Error
bars represent the SEM. (C) Representative im-
munoblot analysis for b-catenin in the colonic ep-
ithelium of transgenic and nontransgenic mice.
(D) Densitometric analysis of b-catenin expres-
sion. Results were normalized to b-catenin in
wild-type mice. n 5 6 for each group. Error bars
represent SEM. Equal amounts of total protein
were analyzed in each immunoblot.
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cinogenesis (Pennisi, 1998). Mutations in either APC or
b-catenin that disrupt b-catenin degradation are present in
the vast majority of colon cancers, providing strong evi-
dence that elevated b-catenin levels are important in colon
carcinogenesis (Ilyas et al., 1997; Pennisi, 1998). Further-
more, overexpression of a proteolytically-stable NH2-ter-
minal truncated b-catenin in the intestinal epithelium of
transgenic mice leads to hyperproliferation (Wong et al.,
1998). Our data suggest that accumulation of b-catenin
through PKC bII–mediated inhibition of GSK-3b may play
an important promotive role in colon carcinogenesis be-
fore the acquisition of mutations in members of this criti-
cal signaling pathway.
A major question is how PKC bII activity is modulated
during the early stages of colon carcinogenesis. One at-
tractive hypothesis arises from the finding that colonocyte
PKC activity can be stimulated by cancer-promotive com-
ponents of a high fat diet. Diets high in certain fatty acids
have been shown to increase the proliferative activity of
the colonic epithelium, stimulate colonocyte PKC activity,
and increase susceptibility to carcinogen-induced ACF
(Craven and DeRubertis, 1988; Risio et al., 1996, Moro-
tomi et al., 1997). This finding is of significance since in-
creased colonic proliferation is a well-established risk fac-
tor and biomarker for colon cancer in individuals with
familial adenomatous polyposis and ulcerative colitis, as
well as in carcinogen-treated rodents (Einspahr et al.,
1997).
Cancer-promotive dietary fats function to increase the
level of secondary bile acid and fatty acids in the intestinal
lumen. Secondary bile acids can in turn activate colonic
PKC by a number of mechanisms. First, secondary bile ac-
ids and fatty acids can directly activate PKC bII activity
and stimulate cellular proliferation in the colonic epithe-
lium (DeRubertis et al., 1984; Fitzer et al., 1987; Ward and
O’Brian, 1988; Pongracz et al., 1995). Second, bile acids
can promote DAG production by intestinal bacteria,
which in turn stimulate colonocyte PKC activity (Moro-
tomi et al., 1990; Morotomi et al., 1991). Third, bile acids
can stimulate phospholipid breakdown and DAG genera-
tion in colonic epithelial cells (DeRubertis and Craven,
1987), leading to PKC activation. Therefore, we hypothe-
size that these dietary risk factors increase PKC bII activity
in intestinal epithelial cells by multiple mechanisms, re-
Figure 8. Model of a proposed functional role for PKC bII in colon carcinogenesis. PKC bII is proposed to function in the Wnt signaling
pathway in the colonic epithelium. (A) During embryogenesis, Wnt signals through Dsh to PKC bII, which phosphorylates GSK-3b to
inhibit its activity. b-catenin levels rise, leading to Tcf-dependent activation of transcription of growth-related genes. (B) In the adult
colonocyte, Wnt is not present, GSK-3b activity is constitutively high, and APC binds b-catenin and targets it for degradation. (C) In
transgenic PKC bII mice, PKC bII levels and activity are elevated. PKC bII can induce phosphorylation and inactivation of GSK-3b.
b-catenin levels rise and Tcf-dependent transcription of growth-related genes is induced, leading to increased proliferation. Similarly,
AOM treatment leads to increased expression of PKC bII stimulating this proliferative pathway during colon carcinogenesis. Biochemi-
cal evidence suggests that PKC bII can be activated by various lipid components of a cancer-promotive diet, including free fatty acids,
secondary bile acids, and bacterially-derived DAG. Direct stimulation of PKC bII by these factors leads to Wnt-independent activation
of the APC/b-catenin signaling pathway, hyperproliferation, and enhanced susceptibility to colon carcinogenesis.
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sulting in increased epithelial cell proliferation through ac-
tivation of the APC/b-catenin signaling pathway in a Wnt-
independent fashion (Fig. 8 C). This model provides a
plausible link between a critical intracellular signaling
pathway that is known to be important in colon cancer,
and known dietary risk factors for colon carcinogenesis.
Our transgenic PKC bII mice will provide a valuable
model to test the hypothesis that PKC bII is a relevant tar-
get for these cancer-promotive dietary risk factors, and to
explore the mechanism by which these factors may im-
pinge on the APC/b-catenin signaling pathway.
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